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Empirical initial meropenem monotherapy allowed
withholding of vancomycin in febrile neutropenic chil-
dren with implanted central venous catheters.
Cancer children with fever and neutropenia are at
high risk for bacterial infections and require prompt
antimicrobial therapy [3]. Since implanted central ve-
nous catheters (ICVC) provide an additional risk for
infectious complications [6] and are increasingly used
in these children, we evaluated their impact on the
need to complement initial empirical carbapenem
monotherapy.
During a 24-month period, we prospectively evalu-
ated 41 cancer children aged 0.3 to 15.4 years (mean 5.9
years; median 6.1 years) with ICVC (Port-a-Cath,
Pharmacia, Du¨bendorf, Switzerland) manifesting 82
episodes of fever (axillary temperature >38.5C once or
>38.0C on >2 occasions within 12 h) and neutropenia
(<500 neutrophils/ll). A total of 33 episodes occurred
in 19 children with acute lymphatic leukaemia, 23 in six
with acute myelogenous leukaemia, two in two with
lymphoma, and 24 in 14 with solid tumours. Empirical
treatment was started with meropenem (20 mg/kg tid).
When fever and neutropenia persisted and cultures were
negative after 48 h, vancomycin (40 mg/kg per day) and
after another 48 h amphotericin B (0.6 to 1.2 mg/kg per
day) was added. Antimicrobials were continued for 5
days after defervescence or termination of neutropenia
and, if a pathogen was isolated, treatment was continued
for 14 days according to susceptibility testing.
Of 82 episodes, 23 (28%)were microbiologically
documented, including 18 bacteraemias, two urinary
tract and three viral infections (Table 1), 28 (34%) were
clinically documented and 31 (38%) were unexplained.
Bacteraemia was caused by gram-positive bacteria in 15
(83%) episodes (Table 1); 14 (78%) of these isolates
were meropenem-susceptible, as were Escherichia coli
and Citrobacter spp.isolated from urine. No invasive
fungal infection was diagnosed. Neutropenic fever per-
sisting >48 h demanded addition of vancomycin in 35
(43%) episodes and after 96 h of amphotericin B in 12%
(Table 1). Isolation of meropenem-resistant bacteria
demanded vancomycin addition in four (5%) episodes.
Since symptoms were not severe and patients did not
deteriorate, vancomycin was not given before 48 h, i.e.
not before meropenem resistance of the isolate was
known. Repeated isolation of the same species from
blood in three of four children suggested colonisation of
the ICVC and its removal resulted in resolution of fever.
Initial empirical meropenem monotherapy for febrile
neutropenia in cancer children with ICVC was eﬀective.
The incidence of bacteraemia (22% of episodes) was
similar to that in previous reports of children [2, 4, 5].
The high rate of gram-positive bacteraemias (83%) ex-
tends the shift towards gram-positive infections [2, 3, 4]
and may be inﬂuenced by the universal presence of
ICVC. Although the catheter frequency in children in
previous studies ranged from 82% to 90% [2, 4], its
relevance with respect to infections was not investigated.
All meropenem-resistant bacteria isolated from blood
(5% of episodes) were gram-positive, susceptible to
vancomycin, and caused no life-threatening infections.
Three of four resistant isolates grew from contaminated
ICVC. Withholding vancomycin until the meropenem
resistance of the isolate was known resulted in no dis-
advantage for the patients. Such a procedure, optional
in recent recommendations [3], would allow a vanco-
mycin restriction of up to 100% within the ﬁrst 48 h. In
our cohort this translates to a prevention of vancomycin
exposure by 164 days. We added vancomycin after 48 h
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in 43% of episodes which is within the range of
25%–50% reported in other paediatric studies [1, 2, 4].
Although this study was non-comparative, the very
low proportion of meropenem-resistant isolates still
justiﬁes our conclusion that vancomycin is initially not
needed in addition to empirical meropenem treatment in
febrile neutropenic cancer children with ICVC. Admin-
istration of vancomycin is to be added only following
isolation of meropenem-resistant bacteria or on demand
by escalation guidelines.
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Table 1 Febrile neutropenic
episodes (n =82) in 41 cancer
children during a 24-month
period. Episodes were classiﬁed
as microbiologically
documented (including 18
bacteraemias, two urinary tract
and three viral infections),
clinically documented (site of
infection identiﬁed, no
organism isolated) and
unexplained fever (infection
most likely, no site or organism
identiﬁed)
Episode N Meropenem-resistant Escalation
Plus
vancomycin
Plus
amphotericin B
Microbiologically documented 23 4 16 4
Bacteraemia due to: 18 4/18
Streptococcus mitis 0/5
Staphylococcus epidermidis 2/4
Escherichia coli 0/3
Streptococcus oralis 0/2
Staphylococcus aureus 0/1
Staphylococcus hominis 0/1
Stomatococcus mucilaginosus 1/1
Bacillus cereus 0/1
Clinically documented 28 10 3
Unexplained fever 31 9 3
Total 82 4 (5%) 35 (43%) 10 (12%)
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